Product Name:
IKZF1-pY413
Product Number:
ab-pn707
Target Full Name: DNA-binding protein IKZF1 (Ikaros)
Target Alias: DNA-binding protein Ikaros; HIk-1; Hs.54452; Ik1; Ikar; Ikaros; IKAROS; IKAROS family zinc finger 1; Ikzf1; Lyf1; LyF-1; Lymphoid transcription factor LyF-1; Zinc finger protein, subfamily 1A, 1 (Ikaros); Znfn1a1
Product Type Specific: IKZF1 phosphosite-specific antibody
Antibody Code: PN707
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y413
Protein UniProt: Q13422
Protein SigNET: IKZF1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human IKZF1
Antibody Immunogen Sequence: GLI(pY)LTN(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues G410 to N416. Y413 phosphorylation induces transcription. This is the major in vivo phosphorylation site in IKZF1 (≥94 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). This human phosphosite is highly conserved in vertebrates and also found in the chicken.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.3 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Dog | Rat | Mouse | Platypus | Chicken.
Related Product 1: IKZF1 S361+S364 phosphorylation antibody (Cat. No.: AB-PN797)
Scientific Background: IKZF1 (DNA-binding protein Ikaros) is a 58 kDa transcription regulator of hematopoietic cell differentiation that belongs to the Ikaros C2H2-type zinc-finger protein family. It features four N-terminal zinc fingers for DNA binding and two C-terminal zinc fingers for dimerization/interaction with other proteins. It binds gamma-satellite DNA, and activates the enhancer (delta-A element) of the CD3-delta gene. It plays a role in the development of lymphocytes, B- and T-cells, and increases normal apoptosis in adult erythroid cells. It acts as a repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. It regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. It targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta-globin locus in adult erythrocytes. IKZF1 confers early temporal competence to retinal progenitor cells (RPCs). The functions of IKZF1 are isoform-specific and are modulated by dominant-negative inactive isoforms. It maintains homeostasis and prevents leukemia by regulating self-renewal and growth, particularly in B-cell precursors. It is primarily located in the nucleus of cells, and it is abundantly expressed in thymus, spleen and peripheral blood Leukocytes and lymph nodes, with lower expression in bone marrow and small intestine. Dysfunction of IKZF1 is highly associated with high-risk B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and B-cell non-Hodgkin lymphomas. IKZF1 deletions or mutations are frequent (up to 40% in adults) in B-cell acute lymphoblastic leukemia (B-ALL) and are associated with poor prognosis. It is also a target for degradation by immunomodulatory drugs (e.g., lenalidomide) in treating hematologic malignancies. This description may include information annotated by UniProt and/or Google AI.